{
    "root": "d52a823a-35bd-4c6a-a016-4b4f21a43d7d",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Jesduvroq",
    "value": "20230830",
    "ingredients": [
        {
            "name": "DAPRODUSTAT",
            "code": "JVR38ZM64B"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        }
    ],
    "indications": "jesduvroq indicated treatment anemia due chronic kidney disease ( ckd ) adults receiving dialysis least four months . limitations jesduvroq shown improve quality life , fatigue , patient well-being . jesduvroq indicated : \u2022as substitute red blood cell transfusions patients require immediate correction anemia . \u2022for treatment anemia chronic kidney disease patients dialysis .",
    "contraindications": "\u2022 administer orally daily , without food . ( 2.2 , 2.3 ) \u2022 full prescribing information starting based hemoglobin level , liver function concomitant medications , dose titration monitoring recommendations . ( 2.3 , 2.4 , 2.5 , 2.6 )",
    "warningsAndPrecautions": "supplied jesduvroq tablets contain 1 mg , 2 mg , 4 mg , 6 mg 8 mg daprodustat . tablet strength package configuration ndc number tablet description markings 1 mg 30 count bottle ( ndc 0173-0897-13 ) round , gray , biconvex , film-coated tablets debossed \u201c gs kf \u201d one side 100 count blister pack ( ndc 0173-0897-56 ) 2 mg 30 count bottle ( ndc 0173-0903-13 ) round , yellow , biconvex , film-coated tablets debossed \u201c gs v7 \u201d one side 100 count blister pack ( ndc 0173-0903-56 ) 4 mg 30 count bottle ( ndc 0173-0906-13 ) round , white , biconvex , film-coated tablets debossed \u201c gs 13 \u201d one side 100 count blister pack ( ndc 0173-0906-56 ) 6 mg 30 count bottle ( ndc 0173-0911-13 ) round , pink , biconvex , film-coated tablets debossed \u201c gs im \u201d one side 100 count blister pack ( ndc 0173-0911-56 ) 8 mg 30 count bottle ( ndc 0173-0914-13 ) round , orange , biconvex , film-coated tablets debossed \u201c gs 5e \u201d one side 100 count blister pack ( ndc 0173-0914-56 ) storage handling store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) . [ usp controlled room temperature ] .",
    "adverseReactions": "jesduvroq contraindicated patients : \u2022receiving strong cyp2c8 inhibitor gemfibrozil [ ( 7.1 ) , pharmacology ( 12.3 ) ] . \u2022with uncontrolled hypertension [ ( 5.3 ) ] .",
    "indications_original": "JESDUVROQ is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months.\n                  \n                     Limitations of Use\n                  \n                  JESDUVROQ has not been shown to improve quality of life, fatigue, or patient well-being.\n                  JESDUVROQ is not indicated for use:\n                  \n                     \n                        \u2022As a substitute for red blood cell transfusions in patients who require immediate correction of anemia.\n                     \n                        \u2022For treatment of anemia of chronic kidney disease in patients who are not on dialysis.",
    "contraindications_original": "\u2022 Administer orally once daily, with or without food. ( 2.2 , 2.3 ) \u2022 See Full Prescribing Information for starting dosage based on hemoglobin level, liver function and concomitant medications, and for dose titration and monitoring recommendations. ( 2.3 , 2.4 , 2.5 , 2.6 )",
    "warningsAndPrecautions_original": "How Supplied\n                  \n                  JESDUVROQ tablets contain 1 mg, 2 mg, 4 mg, 6 mg or 8 mg of daprodustat.\n                  \n                     \n                     \n                     \n                     \n                        \n                           \n                              \n                                 Tablet\n                              \n                              \n                                 Strength\n                              \n                           \n                           \n                              \n                                 Package Configuration\n                              \n                              \n                                 and NDC Number\n                              \n                           \n                           \n                              \n                                 Tablet Description\n                              \n                              \n                                 and Markings\n                              \n                           \n                        \n                        \n                           \n                              1 mg\n                           \n                           \n                              30 count bottle\n                              (NDC 0173-0897-13)\n                           \n                           \n                              Round, gray, biconvex, film-coated tablets debossed with \u201cGS KF\u201d on one side\n                           \n                        \n                        \n                           \n                              100 count blister pack\n                              (NDC 0173-0897-56)\n                           \n                        \n                        \n                           \n                              2 mg\n                           \n                           \n                              30 count bottle\n                              (NDC 0173-0903-13)\n                           \n                           \n                              Round, yellow, biconvex, film-coated tablets debossed with \u201cGS V7\u201d on one side\n                           \n                        \n                        \n                           \n                              100 count blister pack\n                              (NDC 0173-0903-56)\n                           \n                        \n                        \n                           \n                              4 mg\n                           \n                           \n                              30 count bottle\n                              (NDC 0173-0906-13)\n                           \n                           \n                              Round, white, biconvex, film-coated tablets debossed with \u201cGS 13\u201d on one side\n                           \n                        \n                        \n                           \n                              100 count blister pack\n                              (NDC 0173-0906-56)\n                           \n                        \n                        \n                           \n                              6 mg\n                           \n                           \n                              30 count bottle\n                              (NDC 0173-0911-13)\n                           \n                           \n                              Round, pink, biconvex, film-coated tablets debossed with \u201cGS IM\u201d on one side\n                           \n                        \n                        \n                           \n                              100 count blister pack\n                              (NDC 0173-0911-56)\n                           \n                        \n                        \n                           \n                              8 mg\n                           \n                           \n                              30 count bottle\n                              (NDC 0173-0914-13)\n                           \n                           \n                              Round, orange, biconvex, film-coated tablets debossed with \u201cGS 5E\u201d on one side\n                           \n                        \n                        \n                           \n                              100 count blister pack\n                              (NDC 0173-0914-56)\n                           \n                        \n                     \n                  \n                  \n                     Storage and Handling\n                  \n                  Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted between 15\u00b0C and 30\u00b0C (59\u00b0F to 86\u00b0F). [See USP Controlled Room Temperature].",
    "adverseReactions_original": "JESDUVROQ is contraindicated in patients:\n                  \n                     \n                        \u2022Receiving a strong CYP2C8 inhibitor such as gemfibrozil [see Drug Interactions (7.1), Clinical Pharmacology (12.3)].\n                     \n                        \u2022With uncontrolled hypertension [see Warnings and Precautions (5.3)]."
}